This site is intended for healthcare professionals based in the U.K. Click here if you are a patient or a carer.

HAE treatment

If left untreated, attacks gradually worsen over a 24-hour period and typically subside within 3 to 5 days.1–3 Treatment for HAE should be individualised to your patient’s needs and lifestyle to help reduce the burden of disease by preventing or attenuating attacks.4

HAE can be managed with:

 

Use

Acute therapy4

For the treatment of acute attacks of HAE

Short-term prophylactic therapy4

For the prevention of HAE attacks in patients with planned exposure to a situation likely to trigger an attack, such as dentistry and invasive medical and surgical procedures

Long-term prophylactic therapy4

To minimise the frequency and severity of recurrent attacks

 

According to the 2014 UK Consensus Guidelines, some of the key management strategies for HAE include:5

  • All disabling attacks, irrespective of location, are eligible for treatment as soon as they are clearly recognised5
  • Every patient (including children) should be offered the option of home administration with appropriate monitoring, training and governance5
  • Every patient should hold a safe quantity (minimum of one) of acute treatment doses at home, dependent on individual needs5
  • All patients should have a treatment plan for acute and elective surgery, including dentistry5
  • Regular prophylactic treatment may be appropriate for patients requiring treatment for two or more attacks per week5

 

Please note that current treatment guidelines are for patients with Type I and Type II HAE only; the pathogenesis of other forms of HAE is not well-characterised, and therefore, therapeutic options may not be similarly effective.

References: 

  1. Longhurst H, et al. Lancet 2012;379(9814):474–81.
  2. HAE UK. Available from: https://www.haeuk.org/what-is-hae/ Accessed August 2021.
  3. Henao MP, et al. Ther Clin Risk Manag 2016;12:701–11.
  4. Maurer M, et al. Allergy 2018;73(8):1575–96.
  5. Longhurst HJ, et al. Clin Exp Immunol 2015;180(3):475–83.
Job code: C-ANPROM/UK//2468 Date of preparation: August 2021